Half Year 2022 Mayne Pharma Group Ltd Earnings Call Transcript
Good day, and welcome to the Mayne Pharma Half Year Results Conference Call. At this time, I would like to turn the conference over to Mr. Scott Richards, the CEO of the company. Please go ahead, sir. Thank you.
Thank you, operator, and good morning, everybody. Thank you for joining us today to discuss Mayne Pharma's half year results for 2022. And joining me on the call is Peter Paltoglou, our Chief Financial Officer.
Today, I will provide you with an overview of the results together with the business and strategy update, and Peter will provide further details on the financial results, and then we'll open up the call to questions.
On Slide 5, we outline the key financials. Revenues were $196 million. Reported EBITDA was $49 million, and underlying EBITDA was $24 million.
Removing the impact of our launch investment in NEXTSTELLIS from the results, underlying EBITDA was $44 million, up 11% from the prior corresponding period and up 35% on the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
